NCCN Guidelines Insights: Prostate Cancer, Version 1.2021
Edward M. Schaeffer(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Sandy Srinivas(Cancer Institute (WIA)), Emmanuel S. Antonarakis(Sidney Kimmel Comprehensive Cancer Center), Andrew J. Armstrong(Cancer Institute (WIA)), Justin E. Bekelman(University of Pennsylvania), Heather H. Cheng(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Anthony V. D’Amico(Massachusetts General Hospital), Brian J. Davis, Neil Desai(Southwestern Medical Center), Tanya B. Dorff(City Of Hope National Medical Center), James A. Eastham(Memorial Sloan Kettering Cancer Center), Thomas A. Farrington(Fox Chase Cancer Center), Xin Gao(Massachusetts General Hospital), Eric M. Horwitz(Novartis (Switzerland)), Joseph E. Ippolito(Barnes-Jewish Hospital), Michael Kuettel(Novartis (Switzerland)), Joshua M. Lang(University of Wisconsin Carbone Cancer Center), Rana R. McKay(University of California San Diego), Jesse K. McKenney(Cleveland Clinic), George J. Netto(University of Colorado Cancer Center), David F. Penson(Novartis (Switzerland)), Julio M. Pow‐Sang(Moffitt Cancer Center), Robert E. Reiter(UCLA Jonsson Comprehensive Cancer Center), Sylvia Richey(St. Jude Children's Research Hospital), Mack Roach(UCSF Helen Diller Family Comprehensive Cancer Center), Stan Rosenfeld(University of California, San Francisco), Ahmad Shabsigh(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Daniel E. Spratt(Susan Thompson Buffett Foundation), Benjamin A. Teply(Novartis (Switzerland)), Jonathan D. Tward(University of Utah), Dorothy A. Shead(National Comprehensive Cancer Network), Deborah A. Freedman-Cass(National Comprehensive Cancer Network)
Cited by 530Open Access
Abstract
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of recurrent disease are also included. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. This article summarizes the panel's discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.